Advertisement
Advertisement
U.S. markets open in 6 hours 4 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Dyne Therapeutics, Inc. (DYN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Visitors trend2W10W9M
11.18-0.30 (-2.61%)
At close: 04:00PM EDT
11.25 +0.07 (+0.63%)
After hours: 05:24PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Performance Outlook
Previous Close11.48
Open11.60
Bid0.00 x 800
Ask0.00 x 800
Day's Range10.94 - 11.66
52 Week Range4.30 - 15.63
Volume294,083
Avg. Volume305,191
Market Cap629.861M
Beta (5Y Monthly)0.28
PE Ratio (TTM)N/A
EPS (TTM)-3.02
Earnings DateMay 01, 2023 - May 05, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est29.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for DYN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Dyne Therapeutics, Inc.
    Analyst Report: CMS Energy CorporationCMS Energy is an energy holding company with three principal businesses. Its regulated utility, Consumers Energy, provides regulated natural gas service to 1.8 million customers and electric service to 1.9 million customers in Michigan. CMS Enterprises is engaged in wholesale power generation, including contracted renewable energy. CMS sold EnerBank in October 2021.
    Rating
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more
  • GlobeNewswire

    Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy

    - Data from the Global, Multiple Ascending Dose Phase 1/2 DELIVER Clinical Trial Anticipated in the Second Half of 2023 - WALTHAM, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that DYNE-251, an investigational therapeutic for Duchenne muscular dystrophy (DMD) mutations amenable to exon 51 ski

  • GlobeNewswire

    Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference

    - Company Presents Overviews of ACHIEVE and DELIVER Global Clinical Trials with Data Anticipated from Both Studies in the Second Half of 2023 - - FORCE™ Platform Achieves Robust Exon Skipping, Restores Dystrophin at the Sarcolemma and Halts Progression of Fibrosis in a Severe In Vivo Model of Duchenne - WALTHAM, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics fo

  • GlobeNewswire

    Dyne Therapeutics to Present at Upcoming Investor Conferences

    WALTHAM, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in virtual fireside chats at the following investor conferences: Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13, 2023 at 2:40 p.m. ETStifel 2023 CNS Days on Wednesday, March 29

Advertisement
Advertisement